

RECEIVED
CENTRAL FAX CENTER
SEP 26 2006



GlaxoSmithKline

FAX

To Commissioner for Patents
.....
Company USPTO
.....
Fax 571-273-8300
.....
From Eric J. Kron
.....
Tel 919-483-8961; Facsimile: 919-483-7977
.....
E-mail eric.j.kron@gsk.com
.....
Date 26 Sep 2006 Pages including cover 11
.....
Subject Communication
.....

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com


Re: In re Application of: Jean-Paul Cassart, et al.
Serial No.: 10/650,608
Filing Date: 28 Aug 2003
For: TUMOUR SPECIFIC ANIMAL PROTEINS
Title: *Immunogenic Compositions*
Attorney Docket No. B45311
Examiner: Min-Tam Davis
Art Unit: 1642
Confirmation No: 8978

Attached is:

1. Communication;
2. Exhibits A & B

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Communication is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 571-273-8300) on 26 Sep 2006.


Eric J. Kron

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Serial No. 10/650,608
Page 1 of 3

RECEIVED
CENTRAL FAX CENTER

SEP 26 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jean-Paul Cassart, et al.

Serial No.: 10/650,608

Examiner: Min-Tam Davis

Filing Date: 28 Aug 2003

Art Unit: 1642

For: TUMOUR SPECIFIC ANIMAL
PROTEINS

Confirmation No: 8978

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

To the Examiner:

This paper is submitted responsive to the Examiner Interview conducted 19 Sep 2006. There are no amendments; Remarks begin on the next page.